Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Tirsa T van Duijl"'
Autor:
Tirsa T van Duijl, L Renee Ruhaak, Ellen K Hoogeveen, Renée de Mutsert, Frits R Rosendaal, Saskia le Cessie, Johan W de Fijter, Christa M Cobbaert
Publikováno v:
Annals of Clinical Biochemistry. SAGE PUBLICATIONS INC
Annals of Clinical Biochemistry
Annals of Clinical Biochemistry
Background and Aims There is an ongoing need to recognize early kidney injury and its progression in structural chronic pathologies. The proteins neutrophil-gelatinase-associated lipocalin (NGAL), insulin-like growth factor-binding protein 7 (IGFBP7)
Autor:
Julie M. Janssen, Remy B. Verheijen, Tirsa T. van Duijl, Lishi Lin, Michel M. van den Heuvel, Jos H. Beijnen, Neeltje Steeghs, Daan van den Broek, Alwin D. R. Huitema, Thomas P. C. Dorlo
Publikováno v:
Clinical and Translational Science. 15:1916-1925
Autor:
Nico P.M. Smit, Johan W. de Fijter, Fred P.H.T.M. Romijn, Tirsa T van Duijl, Jan W. Drijfhout, Mervin M Pieterse, Christa M. Cobbaert, Natasja Dolezal, L. Renee Ruhaak
Publikováno v:
Journal of Proteome Research. American Chemical Society ({ACS})
Journal of Proteome Research
Journal of Proteome Research
Kidney injury is a complication frequently encountered in hospitalized patients. Early detection of kidney injury prior to loss of renal function is an unmet clinical need that should be targeted by a protein-based biomarker panel. In this study, we
Autor:
Julie M, Janssen, Remy B, Verheijen, Tirsa T, van Duijl, Lishi, Lin, Michel M, van den Heuvel, Jos H, Beijnen, Neeltje, Steeghs, Daan, van den Broek, Alwin D R, Huitema, Thomas P C, Dorlo
Publikováno v:
Clinical and translational science. 15(8)
Correlations between increasing concentrations of circulating tumor DNA (ctDNA) in plasma and disease progression have been shown. A nonlinear mixed effects model to describe the dynamics of epidermal growth factor receptor (EGFR) ctDNA data from pat
Publikováno v:
JOURNAL OF APPLIED LABORATORY MEDICINE, 7(4), 923-930. OXFORD UNIV PRESS INC
Background LC-MS/MS has enabled the translation of many novel biomarkers to the clinical laboratory, but its potential for measurement of urinary proteins is still unexplored. In this study we examined the correlation and agreement between immunoassa
Acute kidney injury (AKI) is a frequent complication in hospitalised patients and is diagnosed by urinary output and serum creatinine. Serum creatinine is an indirect marker for renal glomerular filtration, but lacks specificity for damage to kidney
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e852a9f354c393d70bd0549129b0469
https://europepmc.org/articles/PMC6544249/
https://europepmc.org/articles/PMC6544249/
Autor:
Tirsa T. van Duijl, Dong Guo, Laura H. Heitman, Maxime Heezen, Adriaan P. IJzerman, Gabrielle S. Dijksteel
Publikováno v:
Biochemical Pharmacology. 105:34-41
Classical evaluation of target selectivity is usually undertaken by measuring the binding affinity of lead compounds against a number of potential targets under equilibrium conditions, without considering the kinetics of the ligand-receptor interacti
Autor:
Eelke B. Lenselink, Jacobus P. D. van Veldhoven, Tirsa T. van Duijl, Laura H. Heitman, Adriaan P. IJzerman, Boaz J. Kuiper, Ellen Paasman, Lizi Xia, Wessel A.C. Burger
Publikováno v:
Journal of Medicinal Chemistry
Journal of Medicinal Chemistry, 60(17), 7555-7568
Journal of Medicinal Chemistry, 60(17), 7555-7568. AMER CHEMICAL SOC
Journal of Medicinal Chemistry, 60(17), 7555-7568
Journal of Medicinal Chemistry, 60(17), 7555-7568. AMER CHEMICAL SOC
We expanded on a series of pyrido[2,1-f]purine-2,4-dione derivatives as human adenosine A3 receptor (hA3R) antagonists to determine their kinetic profiles and affinities. Many compounds showed high affinities and a diverse range of kinetic profiles.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::06ecab5d892365671aa9093720b68b2e
https://hdl.handle.net/1887/135658
https://hdl.handle.net/1887/135658
Autor:
Remy B. Verheijen, Jan H.M. Schellens, Jos H. Beijnen, Neeltje Steeghs, Daan van den Broek, Michel M. van den Heuvel, Alwin D. R. Huitema, Tirsa T van Duijl
Publikováno v:
Journal of Clinical Oncology. 35:11535-11535
11535 Background: Epidermal growth factor receptor (EGFR) inhibitors such as erlotinib and gefitinib are routinely used in the treatment of non-small cell lung cancer (NSCLC). Monitoring of EGFR mutations in circulating tumor DNA (ctDNA) derived from